Molina’s 1Q adjusted EPS has surpassed estimates at $5.73 versus the estimate of $5.62 and a previous year figure of $5.81.
The revenue for this quarter was $9.93 billion, indicative of a 22% growth year over year; significantly higher than the projected $9.45 billion.
Medical care ratio stands at 88.5% as compared to 87.1% the previous year.
For the year 2024, the company has reassured that it expects its full year adjusted earnings per diluted share to reach at least $23.50. This represents an approximated 13% growth from the full year 2023.
Premium revenue for the full year is poised to reach approximately $38 billion, showing an increase of almost 17% from the full year 2023.
The company currently holds six buys, nine holds, and one sell.
A look at Molina Healthcare Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Molina Healthcare shows a promising long-term outlook. With high scores in Growth and Resilience, the company is positioned for future expansion and stability. The strong Momentum score indicates positive market sentiment and investor interest in the company’s potential. Although the Value and Dividend scores are lower, the overall outlook remains optimistic for Molina Healthcare.
Molina Healthcare Inc. is a managed care organization focusing on delivering health care services to individuals eligible for Medicaid and other low-income programs. With health plans in multiple states and primary care clinics, Molina Healthcare has established a significant presence in the healthcare industry. The company’s impressive Growth and Resilience scores suggest a resilient business model with potential for continued success and growth in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
